{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:23:44Z","timestamp":1793316224995,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Infective endocarditis (IE) requires prolonged intravenous antibiotic therapy, leading to extended hospitalization and increased morbidity. Dalbavancin, a long-acting antibiotic with excellent tissue penetration and a favorable safety profile, can be a promising alternative. This systematic review aimed to investigate the current literature regarding the use of dalbavancin for infective endocarditis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed and Scopus was conducted according to PRISMA guidelines. Eligible studies included adult patients (\u2265\u200918 years) with IE diagnosed by the modified Duke criteria, treated with dalbavancin as monotherapy or sequential\/consolidation therapy. Data extraction included demographics, type of IE, causative pathogen, dosing regimen, surgical intervention, adverse events, and outcomes. Descriptive analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-eight studies including 565 patients were analyzed. The overall cure rate was 88.0%, with a similar success rate across native valve (90.1%), prosthetic valve (90.0%), and cardiac device-related IE (86.0%).\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      , Coagulase-negative staphylococci (CNS),\n                      <jats:italic>Streptococcus spp<\/jats:italic>\n                      ., and\n                      <jats:italic>Enterococcus faecalis<\/jats:italic>\n                      were the most common pathogens. Cure rates were comparable among most pathogens, though a lower cure rate was evident in infections due to\n                      <jats:italic>Enterococcus faecalis<\/jats:italic>\n                      compared to\n                      <jats:italic>Streptococcus spp.<\/jats:italic>\n                      (80.7% vs. 96.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008). An effective antimicrobial exposure of 2 weeks had similar success rate compared to a longer period of effective antimicrobial exposure (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.31). Adverse events were rare (2.9%), with mild rash being the most common.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dalbavancin demonstrates high cure rates and excellent tolerability in IE, and could offer an attractive alternative to conventional prolonged intravenous therapy. Further randomized controlled trials are warranted to define standardized protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10096-026-05434-3","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T04:33:18Z","timestamp":1770697998000},"page":"931-941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dalbavancin for infective endocarditis: A systematic review of effectiveness, safety, and dosing"],"prefix":"10.1007","volume":"45","author":[{"given":"Anastasios E","family":"Chaldoupis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Petrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina A","family":"Tsante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deny","family":"Tsakri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aglaia","family":"Domouchtsidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Baliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Vlachaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Mpakosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios P","family":"Fortis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Samonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozeta","family":"Sokou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanos","family":"Bonovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Siasos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas G","family":"Tsantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"5434_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1001\/jama.2018.7596","volume":"320","author":"A Wang","year":"2018","unstructured":"Wang A, Gaca JG, Chu VH (2018) Management considerations in infective endocarditis: A review. JAMA 320:72\u201383","journal-title":"JAMA"},{"key":"5434_CR2","first-page":"e29182","volume":"14","author":"SP Kamde","year":"2022","unstructured":"Kamde SP, Anjankar A (2022) Pathogenesis, Diagnosis, antimicrobial Therapy, and management of infective Endocarditis, and its complications. Cureus 14:e29182","journal-title":"Cureus"},{"key":"5434_CR3","doi-asserted-by":"publisher","first-page":"ofac442","DOI":"10.1093\/ofid\/ofac442","volume":"9","author":"JM Pericas","year":"2022","unstructured":"Pericas JM, Llopis J, Munoz P, Gonzalez-Ramallo V, Garcia-Leoni ME, de Alarcon A et al (2022) Outpatient parenteral antibiotic treatment vs hospitalization for infective endocarditis: validation of the OPAT-GAMES criteria. Open Forum Infect Dis 9:ofac442","journal-title":"Open Forum Infect Dis"},{"key":"5434_CR4","doi-asserted-by":"crossref","unstructured":"Rajaratnam D, Rajaratnam R (2023) Outpatient parenteral antimicrobial therapy for infective Endocarditis-Model of care. Antibiot (Basel) 12","DOI":"10.3390\/antibiotics12020355"},{"key":"5434_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2146\/ajhp070255","volume":"65","author":"J Bailey","year":"2008","unstructured":"Bailey J, Summers KM (2008) Dalbavancin: a new lipoglycopeptide antibiotic. Am J Health Syst Pharm 65:599\u2013610","journal-title":"Am J Health Syst Pharm"},{"key":"5434_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40262-021-01088-w","volume":"61","author":"KC Molina","year":"2022","unstructured":"Molina KC, Miller MA, Mueller SW, Van Matre ET, Krsak M, Kiser TH (2022) Clinical pharmacokinetics and pharmacodynamics of Dalbavancin. Clin Pharmacokinet 61:363\u2013374","journal-title":"Clin Pharmacokinet"},{"key":"5434_CR7","doi-asserted-by":"publisher","first-page":"106960","DOI":"10.1016\/j.ijantimicag.2023.106960","volume":"62","author":"E Senneville","year":"2023","unstructured":"Senneville E, Cuervo G, Gregoire M, Hidalgo-Tenorio C, Jehl F, Miro JM et al (2023) Expert opinion on dose regimen and therapeutic drug monitoring for Long-Term use of dalbavancin: expert review panel. Int J Antimicrob Agents 62:106960","journal-title":"Int J Antimicrob Agents"},{"key":"5434_CR8","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.2147\/DDDT.S313756","volume":"15","author":"M Gatti","year":"2021","unstructured":"Gatti M, Andreoni M, Pea F, Viale P (2021) Real-World use of Dalbavancin in the era of empowerment of outpatient antimicrobial treatment: A careful appraisal beyond approved indications focusing on unmet clinical needs. Drug Des Devel Ther 15:3349\u20133378","journal-title":"Drug Des Devel Ther"},{"key":"5434_CR9","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jacc.2022.03.349","volume":"79","author":"E Yucel","year":"2022","unstructured":"Yucel E, Bearnot B, Paras ML, Zern EK, Dudzinski DM, Soong CP et al (2022) Diagnosis and management of infective endocarditis in people who inject drugs: JACC State-of-the-Art review. J Am Coll Cardiol 79:2037\u20132057","journal-title":"J Am Coll Cardiol"},{"key":"5434_CR10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jiph.2023.04.015","volume":"16","author":"CT Baltin","year":"2023","unstructured":"Baltin CT, Wulf C, Rongisch R, Lehmann C, Wingen-Heimann S, Eisenmenger N et al (2023) Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin - A real-world data and retrospective cost analysis. J Infect Public Health 16:955\u2013963","journal-title":"J Infect Public Health"},{"key":"5434_CR11","first-page":"1222","volume":"27","author":"A De Vito","year":"2023","unstructured":"De Vito A, Fiore V, Colpani A, Zauli B, Fanelli C, Tiseo G et al (2023) The current and future off-label uses of dalbavancin: a narrative review. Eur Rev Med Pharmacol Sci 27:1222\u20131238","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"5434_CR12","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/cid\/ciad271","volume":"77","author":"VG Fowler","year":"2023","unstructured":"Fowler VG, Durack DT, Selton-Suty C, Athan E, Bayer AS, Chamis AL et al (2023) The 2023 Duke-International society for cardiovascular infectious diseases criteria for infective endocarditis: updating the modified Duke criteria. Clin Infect Dis 77:518\u2013526","journal-title":"Clin Infect Dis"},{"key":"5434_CR13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/idr14020032","volume":"14","author":"K Taylor","year":"2022","unstructured":"Taylor K, Williamson J, Luther V, Stone T, Johnson J, Gruss Z et al (2022) Evaluating the use of Dalbavancin for Off-Label indications. Infect Dis Rep 14:266\u2013272","journal-title":"Infect Dis Rep"},{"key":"5434_CR14","doi-asserted-by":"crossref","unstructured":"Gallerani A, Gatti M, Bedini A, Casolari S, Orlando G, Puzzolante C et al (2023) Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections. Antibiotics (Basel) 12","DOI":"10.3390\/antibiotics12111639"},{"key":"5434_CR15","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s10096-024-04783-1","volume":"43","author":"A Diez-Vidal","year":"2024","unstructured":"Diez-Vidal A, Gonzalez-Garcia ME, Marco-Clement I, Azores-Moreno J, Roces-Alvarez P, Marcelo-Calvo C et al (2024) Recurrent bacteremia and endocarditis due to Staphylococcus capitis in a patient with bowen\u2019s disease: a case report. Eur J Clin Microbiol Infect Dis 43:999\u20131002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5434_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ijid.2019.12.008","volume":"91","author":"A Hakim","year":"2020","unstructured":"Hakim A, Braun H, Thornton D, Strymish J (2020) Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with Dalbavancin as an outpatient in a person who injects drugs: A case report. Int J Infect Dis 91:202\u2013205","journal-title":"Int J Infect Dis"},{"key":"5434_CR17","first-page":"003654","volume":"10","author":"FJ Teigell-Munoz","year":"2023","unstructured":"Teigell-Munoz FJ, Mateos-Gonzalez M, Bernal Hertfelder E, Sanchez de Torre A, Garcia-Ferron M, de Caceres Velasco C et al (2023) A Dalbavancin for successful treatment of infective endocarditis caused by Enterococcus faecalis. Eur J Case Rep Intern Med 10:003654","journal-title":"Eur J Case Rep Intern Med"},{"key":"5434_CR18","doi-asserted-by":"publisher","first-page":"116132","DOI":"10.1016\/j.diagmicrobio.2023.116132","volume":"108","author":"JG Cepeda","year":"2024","unstructured":"Cepeda JG, Perona FL, Sanchez IB, Calvo JC, Rico A, Loeches B (2024) Case report: prosthetic aortic valve endocarditis due to Staphylococcus epidermidis with acquired resistance in the walk gene. Diagn Microbiol Infect Dis 108:116132","journal-title":"Diagn Microbiol Infect Dis"},{"key":"5434_CR19","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1017\/ash.2022.229","volume":"2","author":"JJ Tuan","year":"2022","unstructured":"Tuan JJ, Kayani J, Fisher A, Kotansky B, Dembry LM, Datta R (2022) Clinical outcomes following Dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy. Antimicrob Steward Healthc Epidemiol 2:e83","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"5434_CR20","doi-asserted-by":"crossref","unstructured":"Ajaka L, Heil E, Schmalzle S (2020) Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care. Antibiot (Basel) 9","DOI":"10.3390\/antibiotics9100700"},{"key":"5434_CR21","doi-asserted-by":"publisher","first-page":"ofz427","DOI":"10.1093\/ofid\/ofz427","volume":"6","author":"M Spaziante","year":"2019","unstructured":"Spaziante M, Franchi C, Taliani G, D\u2019Avolio A, Pietropaolo V, Biliotti E et al (2019) Serum bactericidal activity levels monitor to guide intravenous Dalbavancin chronic suppressive therapy of inoperable Staphylococcal prosthetic valve endocarditis: A case report. Open Forum Infect Dis 6:ofz427","journal-title":"Open Forum Infect Dis"},{"key":"5434_CR22","doi-asserted-by":"crossref","unstructured":"Ioannou P, Wolff N, Mathioudaki A, Spanias C, Spernovasilis N, Kofteridis DP (2023) Real-World data regarding Dalbavancin use before and during the COVID-19 Pandemic-A Single-Center retrospective study. Antibiotics (Basel) 12","DOI":"10.3390\/antibiotics12071205"},{"key":"5434_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/jcpt.12580","volume":"43","author":"JM Steele","year":"2018","unstructured":"Steele JM, Seabury RW, Hale CM, Mogle BT (2018) Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with Dalbavancin. J Clin Pharm Ther 43:101\u2013103","journal-title":"J Clin Pharm Ther"},{"key":"5434_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12941-022-00507-5","volume":"21","author":"C Evins","year":"2022","unstructured":"Evins C, Lancaster H, Schnee AE (2022) Successful use of Dalbavancin in the treatment of gram positive blood stream infections: a case series. Ann Clin Microbiol Antimicrob 21:16","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"5434_CR25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/cid\/ciy279","volume":"67","author":"S Tobudic","year":"2018","unstructured":"Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C et al (2018) Dalbavancin as primary and sequential treatment for Gram-Positive infective endocarditis: 2-Year experience at the general hospital of Vienna. Clin Infect Dis 67:795\u2013798","journal-title":"Clin Infect Dis"},{"key":"5434_CR26","doi-asserted-by":"publisher","first-page":"e0238522","DOI":"10.1128\/spectrum.02385-22","volume":"11","author":"R Lueking","year":"2023","unstructured":"Lueking R, Wei W, Mang NS, Ortwine JK, Meisner J (2023) Evaluation of Dalbavancin use on clinical Outcomes, Cost-Savings, and adherence at a large safety net hospital. Microbiol Spectr 11:e0238522","journal-title":"Microbiol Spectr"},{"key":"5434_CR27","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ijantimicag.2019.08.006","volume":"54","author":"A Dinh","year":"2019","unstructured":"Dinh A, Duran C, Pavese P, Khatchatourian L, Monnin B, Bleibtreu A et al (2019) French National cohort of first use of dalbavancin: A high proportion of off-label use. Int J Antimicrob Agents 54:668\u2013672","journal-title":"Int J Antimicrob Agents"},{"key":"5434_CR28","doi-asserted-by":"publisher","first-page":"106918","DOI":"10.1016\/j.ijantimicag.2023.106918","volume":"62","author":"C Hidalgo-Tenorio","year":"2023","unstructured":"Hidalgo-Tenorio C, Sadyrbaeva-Dolgova S, Enriquez-Gomez A, Munoz P, Plata-Ciezar A, Miro JM et al (2023) EN-DALBACEN 2.0 cohort: real-life study of Dalbavancin as sequential\/consolidation therapy in patients with infective endocarditis due to Gram-positive Cocci. Int J Antimicrob Agents 62:106918","journal-title":"Int J Antimicrob Agents"},{"key":"5434_CR29","doi-asserted-by":"publisher","first-page":"dlae066","DOI":"10.1093\/jacamr\/dlae066","volume":"6","author":"C Bresges","year":"2024","unstructured":"Bresges C, Bresges K, Hewitt C, Sharma S, Davies B (2024) Three-years of Dalbavancin use at a UK tertiary referral hospital serving a population with high numbers of people who inject drugs. JAC Antimicrob Resist 6:dlae066","journal-title":"JAC Antimicrob Resist"},{"key":"5434_CR30","doi-asserted-by":"publisher","first-page":"ofz028","DOI":"10.1093\/ofid\/ofz028","volume":"6","author":"C Bryson-Cahn","year":"2019","unstructured":"Bryson-Cahn C, Beieler AM, Chan JD, Harrington RD, Dhanireddy S (2019) Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population. Open Forum Infect Dis 6:ofz028","journal-title":"Open Forum Infect Dis"},{"key":"5434_CR31","first-page":"e81505","volume":"17","author":"J Polega","year":"2025","unstructured":"Polega J, Bhugra M, Vanderhorst D, de Sanctis J, Chang A, Hassouna H (2025) Real-World use of Dalbavancin in a united States. Tert Ref Cent Cureus 17:e81505","journal-title":"Tert Ref Cent Cureus"},{"key":"5434_CR32","doi-asserted-by":"crossref","unstructured":"Arnes-Garcia D, Lucena-Torres L, Bustos-Merlo A, Rosales-Castillo A, Hidalgo-Tenorio C (2024) Infective endocarditis due to Corynebacterium jeikeium: four case reports and narrative review of the literature. Microorganisms 12.","DOI":"10.3390\/microorganisms12071337"},{"key":"5434_CR33","doi-asserted-by":"publisher","first-page":"334","DOI":"10.37201\/req\/012.2024","volume":"37","author":"D Brandariz-Nunez","year":"2024","unstructured":"Brandariz-Nunez D, Luances-Rodriguez A, Feijoo-Vilanova P, Gutierrez-Urbon JM, Ramudo-Cela L, Martin-Herranz MI et al (2024) Dalbavancin as consolidation therapy for infective endocarditis in patients with comorbidity. A real world experience. Rev Esp Quimioter 37:334\u2013340","journal-title":"Rev Esp Quimioter"},{"key":"5434_CR34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.eimc.2024.04.009","volume":"43","author":"E Aparicio-Minguijon","year":"2025","unstructured":"Aparicio-Minguijon E, Boan J, Terron A, Heredia C, Puente C, Perez-Jacoiste Asin A et al (2025) Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients. Enferm Infecc Microbiol Clin (Engl Ed) 43:86\u201392","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"5434_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1080\/1120009X.2020.1823119","volume":"33","author":"E Durante-Mangoni","year":"2021","unstructured":"Durante-Mangoni E, Boccia F, Ursi MP, Karruli A, Andini R, Galdo M et al (2021) Dalbavancin for infective endocarditis: a single centre experience. J Chemother 33:256\u2013262","journal-title":"J Chemother"},{"key":"5434_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s15010-020-01526-0","volume":"49","author":"F Hitzenbichler","year":"2021","unstructured":"Hitzenbichler F, Mohr A, Camboni D, Simon M, Salzberger B, Hanses F (2021) Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source-a series of four cases. Infection 49:181\u2013186","journal-title":"Infection"},{"key":"5434_CR37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41426-018-0205-z","volume":"7","author":"M Kussmann","year":"2018","unstructured":"Kussmann M, Karer M, Obermueller M, Schmidt K, Barousch W, Moser D et al (2018) Emergence of a Dalbavancin induced glycopeptide\/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis. Emerg Microbes Infect 7:202","journal-title":"Emerg Microbes Infect"},{"key":"5434_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijid.2023.11.003","volume":"138","author":"M Suarez","year":"2024","unstructured":"Suarez M, Perez-Landeiro A, Sanjurjo A, Lima O, Sousa A, Lopez A et al (2024) Comparison of Dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis. Int J Infect Dis 138:41\u201345","journal-title":"Int J Infect Dis"},{"key":"5434_CR39","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","volume":"81","author":"S Wunsch","year":"2019","unstructured":"Wunsch S, Krause R, Valentin T, Prattes J, Janata O, Lenger A et al (2019) Multicenter clinical experience of real life Dalbavancin use in gram-positive infections. Int J Infect Dis 81:210\u2013214","journal-title":"Int J Infect Dis"},{"key":"5434_CR40","doi-asserted-by":"publisher","first-page":"ofae186","DOI":"10.1093\/ofid\/ofae186","volume":"11","author":"S Zambrano","year":"2024","unstructured":"Zambrano S, Paras ML, Suzuki J, Pearson JC, Dionne B, Schrager H et al (2024) Real-World Dalbavancin use for serious Gram-Positive infections: comparing outcomes between people who use and do not use drugs. Open Forum Infect Dis 11:ofae186","journal-title":"Open Forum Infect Dis"},{"key":"5434_CR41","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1093\/jac\/dkz162","volume":"74","author":"T Morrisette","year":"2019","unstructured":"Morrisette T, Miller MA, Montague BT, Barber GR, McQueen RB, Krsak M (2019) On- and off-label utilization of Dalbavancin and Oritavancin for Gram-positive infections. J Antimicrob Chemother 74:2405\u20132416","journal-title":"J Antimicrob Chemother"},{"key":"5434_CR42","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1080\/14787210.2020.1798227","volume":"18","author":"F Bai","year":"2020","unstructured":"Bai F, Aldieri C, Cattelan A, Raumer F, Di Meco E, Moioli MC et al (2020) Efficacy and safety of Dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study). Expert Rev Anti Infect Ther 18:1271\u20131279","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5434_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","volume":"51","author":"E Bouza","year":"2018","unstructured":"Bouza E, Valerio M, Soriano A, Morata L, Carus EG, Rodriguez-Gonzalez C et al (2018) Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents 51:571\u2013577","journal-title":"Int J Antimicrob Agents"},{"key":"5434_CR44","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1007\/s15010-025-02585-x","volume":"53","author":"CA Darlow","year":"2025","unstructured":"Darlow CA, Parsons J, Lucy D, Li A, Ratcliffe L, Todd S et al (2025) Experience of use of Dalbavancin for the treatment of unlicensed indications in a UK tertiary infectious diseases setting. Infection 53:2503\u20132509","journal-title":"Infection"},{"key":"5434_CR45","doi-asserted-by":"publisher","first-page":"ofaa293","DOI":"10.1093\/ofid\/ofaa293","volume":"7","author":"AA Vazquez Deida","year":"2020","unstructured":"Vazquez Deida AA, Shihadeh KC, Preslaski CR, Young HL, Wyles DL, Jenkins TC (2020) Use of a standardized Dalbavancin approach to facilitate earlier hospital discharge for vulnerable patients receiving prolonged inpatient antibiotic therapy. Open Forum Infect Dis 7:ofaa293","journal-title":"Open Forum Infect Dis"},{"key":"5434_CR46","doi-asserted-by":"publisher","first-page":"dlac120","DOI":"10.1093\/jacamr\/dlac120","volume":"4","author":"L Morata","year":"2022","unstructured":"Morata L, Aguado JM, Salavert M, Pasquau J, Miguez E, Munoz P et al (2022) Dalbavancin in clinical practice in spain: a 2 year retrospective study. JAC Antimicrob Resist 4:dlac120","journal-title":"JAC Antimicrob Resist"},{"key":"5434_CR47","doi-asserted-by":"publisher","first-page":"dlab099","DOI":"10.1093\/jacamr\/dlab099","volume":"3","author":"A Guleri","year":"2021","unstructured":"Guleri A, More R, Sharma R, Wong M, Abdelrahman A (2021) Use of Dalbavancin in infective endocarditis: a case series. JAC Antimicrob Resist 3:dlab099","journal-title":"JAC Antimicrob Resist"},{"key":"5434_CR48","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.eimc.2024.02.010","volume":"43","author":"A Salinas-Botran","year":"2025","unstructured":"Salinas-Botran A, Olmos-Blanco C, Fernandez de Velasco-Perez D, Guzman-Carreras A, Morales-Rosas A, Gomez-Ramirez D (2025) Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: clinical experience of 7 years. Enferm Infecc Microbiol Clin (Engl Ed) 43:71\u201379","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"5434_CR49","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jgar.2024.06.002","volume":"38","author":"G Zhanel","year":"2024","unstructured":"Zhanel G, Silverman M, Malhotra J, Baxter M, Rahimi R, Irfan N et al (2024) Real-life experience with IV Dalbavancin in Canada; results from the CLEAR (Canadian leadership on antimicrobial Real-life usage) registry. J Glob Antimicrob Resist 38:154\u2013157","journal-title":"J Glob Antimicrob Resist"},{"key":"5434_CR50","doi-asserted-by":"publisher","first-page":"106945","DOI":"10.1016\/j.ijantimicag.2023.106945","volume":"62","author":"J Courjon","year":"2023","unstructured":"Courjon J, Senneville E, Illes HG, Pavese P, Boutoille D, Daoud FC et al (2023) Effectiveness and safety of Dalbavancin in france: a prospective, multicentre cohort study. Int J Antimicrob Agents 62:106945","journal-title":"Int J Antimicrob Agents"},{"key":"5434_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s15010-024-02393-9","volume":"53","author":"GM Leanza","year":"2025","unstructured":"Leanza GM, Rando E, Frondizi F, Taddei E, Giovannenze F, Horcajada JP et al (2025) A systematic review of Dalbavancin efficacy as a sequential therapy for infective endocarditis. Infection 53:15\u201323","journal-title":"Infection"},{"key":"5434_CR52","doi-asserted-by":"publisher","first-page":"106749","DOI":"10.1016\/j.ijantimicag.2023.106749","volume":"61","author":"T Fazili","year":"2023","unstructured":"Fazili T, Bansal E, Garner D, Gomez M, Stornelli N (2023) Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review. Int J Antimicrob Agents 61:106749","journal-title":"Int J Antimicrob Agents"},{"key":"5434_CR53","doi-asserted-by":"publisher","first-page":"106072","DOI":"10.1016\/j.ijantimicag.2020.106072","volume":"56","author":"T Lampejo","year":"2020","unstructured":"Lampejo T (2020) Dalbavancin and Telavancin in the treatment of infective endocarditis: a literature review. Int J Antimicrob Agents 56:106072","journal-title":"Int J Antimicrob Agents"},{"key":"5434_CR54","doi-asserted-by":"publisher","first-page":"106069","DOI":"10.1016\/j.ijantimicag.2020.106069","volume":"56","author":"G Thomas","year":"2020","unstructured":"Thomas G, Henao-Martinez AF, Franco-Paredes C, Chastain DB (2020) Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with Dalbavancin and oritavancin: A systematic review. Int J Antimicrob Agents 56:106069","journal-title":"Int J Antimicrob Agents"},{"key":"5434_CR55","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/j.jemermed.2024.03.003","volume":"67","author":"F LoVecchio","year":"2024","unstructured":"LoVecchio F, McCarthy MW, Ye X, Henry AD, Doan QV, Lock JL et al (2024) Single intravenous dose Dalbavancin pathway for the treatment of acute bacterial skin and skin structure infections: considerations for emergency department implementation and cost savings. J Emerg Med 67:e217\u2013e29","journal-title":"J Emerg Med"},{"key":"5434_CR56","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1093\/ajhp\/zxae025","volume":"81","author":"D Donnelly","year":"2024","unstructured":"Donnelly D, Pillinger KE, Debnath A, DePasquale W, Munsiff S, Louie T et al (2024) Cost evaluation of continuation of therapy with Dalbavancin compared to standard-of-care antibiotics alone in hospitalized persons who inject drugs with severe gram-positive infections. Am J Health Syst Pharm 81:S40\u2013S8","journal-title":"Am J Health Syst Pharm"},{"key":"5434_CR57","doi-asserted-by":"crossref","unstructured":"de Pablo-Miro M, Pujol-Ruiz S, Iftimie S, Arenas-Miras MDM, Lopez-Montesinos I, Duran-Jorda X et al (2021) Comparative analysis of Dalbavancin versus other antimicrobial options for Gram-Positive Cocci infections: Effectiveness, hospital stay and mortality. Antibiot (Basel) 10","DOI":"10.3390\/antibiotics10111296"},{"key":"5434_CR58","doi-asserted-by":"crossref","unstructured":"Antosz K, Al-Hasan MN, Lu ZK, Tabor B, Justo JA, Milgrom A et al (2021) Clinical utility and cost effectiveness of Long-Acting lipoglycopeptides used in Deep-Seated infections among patients with social and economic barriers to care. Pharm (Basel) 10","DOI":"10.3390\/pharmacy10010001"},{"key":"5434_CR59","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(24)01098-5","volume":"404","author":"M Li","year":"2024","unstructured":"Li M, Kim JB, Sastry BKS, Chen M (2024) Infective endocarditis. Lancet 404:377\u2013392","journal-title":"Lancet"},{"key":"5434_CR60","unstructured":"Turner NA, Hamasaki T, Doernberg SB, Lodise TP, King HA, Ghazaryan V et al (2025) Dalbavancin for treatment of Staphylococcus aureus bacteremia: the DOTS randomized clinical trial. JAMA"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05434-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05434-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05434-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:02:28Z","timestamp":1776355348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-026-05434-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["5434"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05434-3","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors contributed to the study conception and design. Material preparation was performed by Anastasios E Chaldoupis, Andreas G Tsantes, Aglaia Domouchtsidou, Stella Baliou, Marianna Vlachaki, Alexandra Mpakosi, Sotirios P Fortis and George Samonis. Data collection was performed by Anastasios E Chaldoupis, Andreas G Tsantes, Vasilios Petrakis and Rozeta Sokou. Analysis was performed by Andreas G Tsantes, Gerasimos Siasos, Stefanos Bonovas, Petros Ioannou, Konstantina A Tsante, Deny Tsakri. The first draft of the manuscript was written by Anastasios E. Chaldoupis, Andreas G Tsantes and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The datasets analyzed during the current study are available upon request to the authors of this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}